Urolithin A and Its Effects on Attention and Sleep Timing in Healthcare Workers After Night Shifts
Effects of Urolithin A on Attention and Circadian Rhythm of Sleep in Healthcare Workers After Night Shifts: An Interventional Study
This pilot study will examine whether taking urolithin A helps healthcare workers stay focused after a night shift. It will also look at changes in fatigue, sleepiness, sleep patterns, and the body's internal clock.
The study plans to enroll 40 physicians and nurses aged 24 to 55 who work scheduled night shifts at Henan Provincial People's Hospital. Participants will be assigned by chance, in equal numbers, to take either 1 gram of urolithin A or a matching placebo capsule by mouth once each morning for five consecutive days, starting the day before the night shift. Participants and the study staff who give out the capsules or assess outcomes will not know which group each participant is in. Participants will follow their usual work schedules.
The main measure is the Stroop interference effect, which is the difference in average response time between correct answers when a color word conflicts with its displayed color and correct answers when they match. The researchers will compare how this measure changes from two days before the night shift to the scheduled follow-up assessments in the two groups.
Participants will also rate their fatigue and sleepiness, wear a wrist device to track sleep, keep a sleep diary, and provide saliva samples to measure melatonin. They will complete tasks that measure alertness and the ability to withhold a response during three MRI scans scheduled before the night shift, on the morning the shift ends, and during recovery. The study will help estimate how much the main measure varies among participants to inform a larger trial.
研究概览
地位
详细说明
This single-center, randomized, double-blind, placebo-controlled pilot trial will be conducted at Henan Provincial People's Hospital. After providing written informed consent and completing baseline assessments, participants will be randomly assigned to a study group. An independent team member who is not involved in recruitment, intervention delivery, or outcome assessment will generate the allocation sequence using SAS version 9.4. Coded study products will be dispensed in enrollment order. Group assignments will be kept confidential until the database is locked, except when emergency unblinding is needed for participant safety.
The day on which the scheduled night shift begins is designated Day 0. Baseline assessments will take place on Day -2. Participants will take their assigned study product each morning from Day -1 through Day 3 and will work their usual scheduled night shift. Computerized Stroop testing will be conducted each morning from Day -2 through Day 4 between 07:00 and 09:00. The final assessment will take place on Day 4, after the dosing period has ended.
Task-based functional MRI will be performed at baseline (Day -2), on the morning the night shift ends (Day 1), and during recovery (Day 3). During each scan, participants will complete an 8-minute Psychomotor Vigilance Task and a 6-minute Go/No-Go task. Stimulus timing and button responses will be recorded and synchronized with image acquisition. Wrist activity recordings will be reviewed alongside sleep diaries to distinguish nighttime sleep from daytime naps and identify periods when the device was removed. Saliva will be collected at scheduled times throughout the observation period, with an additional sample at 03:00 during the night shift. Study staff will record actual sample collection times, review dosing and visit records, and document missed doses, concomitant medication use, and adverse events.
Repeated Stroop interference measurements will be analyzed using a linear mixed-effects model with terms for study group, visit, and their interaction, with adjustment for baseline performance and a participant-level random effect. Estimated between-group differences will be reported with 95% confidence intervals. Exploratory analyses will examine whether changes in task-related brain activity are associated with changes in cognitive performance, fatigue, sleepiness, sleep patterns, and salivary melatonin. Visit completion and adherence data will be used to assess the feasibility of the study procedures for a larger trial.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Jie Wang, PhD
- 电话号码:0371-65580020
- 邮箱:imyangsiyu@163.com
研究联系人备份
- 姓名:Haoxiang Xu
- 电话号码:0371-65580020
- 邮箱:xhx0227@163.com
学习地点
-
-
Henan
-
Zhengzhou、Henan、中国、450003
- Henan Provincial People's Hospital
-
接触:
- Jie Wang, PhD
- 电话号码:0371-65580020
- 邮箱:imyangsiyu@163.com
-
接触:
- Liangkai Chen, PhD
- 电话号码:0371-65580020
- 邮箱:clk@hust.edu.cn
-
副研究员:
- Haoxiang Xu, Currently pursuing a master's
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Aged 24 to 55 years, inclusive.
- Physicians or nurses who work scheduled night shifts.
- No history of neurological or psychiatric disorders.
- No diagnosed sleep disorder.
- No contraindications to magnetic resonance imaging (MRI).
- Right-handed.
Exclusion Criteria:
- Recent use of sleep aids or psychoactive medications.
- Severe sleep disruption outside periods of shift work.
- Gastrointestinal disease that may affect urolithin A absorption.
- Pregnancy or breastfeeding.
学习计划
研究是如何设计的?
设计细节
- 主要用途:其他
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:三倍
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Urolithin A
Participants will take 1 g of urolithin A(StanYouth™️ Urolithin A) in capsule form by mouth once daily between 07:00 and 09:00 for five consecutive days, from the day before the scheduled night shift (Day -1) through Day 3. |
Oral urolithin A(StanYouth™️ Urolithin A) capsules at a total daily dose of 1 g. The capsules are taken once each morning between 07:00 and 09:00 for five consecutive days, beginning the day before the scheduled night shift (Day -1) and continuing through Day 3. |
|
安慰剂比较:Matching Placebo
Participants will take 1 g of matching placebo capsules by mouth once daily between 07:00 and 09:00 for five consecutive days, from Day -1 through Day 3. The placebo capsules contain no urolithin A and match the urolithin A capsules in appearance, color, and packaging. |
Oral placebo capsules containing no urolithin A and matching the urolithin A capsules in appearance, color, and packaging. The capsules are taken at a total daily dose of 1 g, once each morning between 07:00 and 09:00 for five consecutive days, from Day -1 through Day 3. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change From Baseline in the Stroop Reaction Time Interference Effect
大体时间:Baseline (Day -2) and follow-up on Days -1, 0, 1, 2, 3, and 4. Day 0 is the day the scheduled night shift begins.
|
At each assessment, the Stroop reaction time interference effect is calculated by subtracting the mean reaction time for valid correct responses in congruent trials from the mean reaction time for valid correct responses in incongruent trials. Reaction times are measured in milliseconds. Change from baseline is calculated as the interference effect at each follow-up assessment minus the baseline interference effect. A positive change indicates greater interference than at baseline. |
Baseline (Day -2) and follow-up on Days -1, 0, 1, 2, 3, and 4. Day 0 is the day the scheduled night shift begins.
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Stroop Reaction Time by Trial Condition,Stroop Response Accuracy by Trial Condition
大体时间:Baseline (Day -2) and Days -1, 0, 1, 2, 3, and 4
|
Mean reaction time, in milliseconds, for valid correct responses on the computerized Stroop task, reported separately for congruent and incongruent trials. Percentage of trials with a correct response on the computerized Stroop task, reported separately for congruent and incongruent trials. |
Baseline (Day -2) and Days -1, 0, 1, 2, 3, and 4
|
|
Psychomotor Vigilance Task
大体时间:Baseline (Day -2), the morning the night shift ends (Day 1), and recovery (Day 3).
|
Mean reaction time, in milliseconds, for valid responses. Premature responses and omissions are excluded. Number of responses with a reaction time of at least 500 milliseconds within the 10-second response window. Number of slow responses divided by [prespecified denominator], multiplied by 100. Number of presented targets for which no response is recorded within 10 seconds. Number of omitted responses divided by[ prespecified denominator], multiplied by 100. Number of premature responses, defined as button presses during the waiting interval or responses occurring less than 100 milliseconds after target onset. |
Baseline (Day -2), the morning the night shift ends (Day 1), and recovery (Day 3).
|
|
Go/No-Go Trial
大体时间:Baseline (Day -2), the morning the night shift ends (Day 1), and recovery (Day 3).
|
Mean reaction time, in milliseconds, for correct responses on Go trials. Percentage of presented Go trials with a valid button press within the response window. Percentage of presented Go trials without a valid button press within the response window. Percentage of presented No-Go trials with a button press within the response window. Percentage of presented No-Go trials without a button press within the response window. |
Baseline (Day -2), the morning the night shift ends (Day 1), and recovery (Day 3).
|
|
Visual Analog Scale for Fatigue Score
大体时间:Baseline (Day -2) and Days -1, 0, 1, 2, 3, and 4.
|
Participants rate their current fatigue on a 100-mm visual analog scale. Scores range from 0 mm (no fatigue) to 100 mm (extreme fatigue), with higher scores indicating greater fatigue. |
Baseline (Day -2) and Days -1, 0, 1, 2, 3, and 4.
|
|
Karolinska Sleepiness Scale Score
大体时间:Baseline (Day -2) and Days -1, 0, 1, 2, 3, and 4.
|
Self-rated sleepiness measured on the 9-point Karolinska Sleepiness Scale. Scores range from 1 to 9, with higher scores indicating greater sleepiness. |
Baseline (Day -2) and Days -1, 0, 1, 2, 3, and 4.
|
|
Fatigue Severity Scale Score
大体时间:Baseline (Day -2) and final follow-up (Day 4).
|
The 9-item Fatigue Severity Scale assesses the impact of fatigue on daily functioning over the past week. Each item is scored from 1 to 7. Item scores are summed to give a total score ranging from 9 to 63, with higher scores indicating a greater impact of fatigue. |
Baseline (Day -2) and final follow-up (Day 4).
|
|
Salivary Melatonin Concentration
大体时间:From 07:00 on Day -2 through the final visit on Day 4. Routine collection times are 07:00, 11:00, 15:00, 19:00, and 23:00, with an additional sample at 03:00 on Day 1.
|
Melatonin concentration measured in saliva samples collected at scheduled times and reported in [laboratory reporting unit]. |
From 07:00 on Day -2 through the final visit on Day 4. Routine collection times are 07:00, 11:00, 15:00, 19:00, and 23:00, with an additional sample at 03:00 on Day 1.
|
|
Actigraphy-Derived Sleep Parameters
大体时间:Continuous monitoring from baseline (Day -2) through final follow-up (Day 4).
|
Total time spent asleep during the recorded sleep episode, estimated from wrist actigraphy and reported in minutes. Percentage of time in bed spent asleep, estimated from wrist actigraphy. Time from attempting to fall asleep to estimated sleep onset, reported in minutes. Total time spent awake after initial sleep onset and before final awakening, estimated from wrist actigraphy and reported in minutes. Number of awakenings detected by wrist actigraphy after initial sleep onset and before final awakening. |
Continuous monitoring from baseline (Day -2) through final follow-up (Day 4).
|
|
Task-Evoked Brain Activation During the Psychomotor Vigilance Task
大体时间:Baseline (Day -2), the morning the night shift ends (Day 1), and recovery (Day 3).
|
Task-evoked brain activation during the Psychomotor Vigilance Task will be quantified using [metric and unit] for [task contrast] in [prespecified regions or whole-brain analysis]. |
Baseline (Day -2), the morning the night shift ends (Day 1), and recovery (Day 3).
|
|
Task-Evoked Brain Activation During the Go/No-Go Task
大体时间:Baseline (Day -2), the morning the night shift ends (Day 1), and recovery (Day 3).
|
Task-evoked brain activation during the Go/No-Go task will be quantified using [metric and unit] for [task contrast] in [prespecified regions or whole-brain analysis]. |
Baseline (Day -2), the morning the night shift ends (Day 1), and recovery (Day 3).
|
合作者和调查者
调查人员
- 研究主任:Jie Wang, PhD、Henan Provincial People's Hospital
- 研究主任:Liangkai Chen, PhD、Huazhong University of Science and Technology
- 研究主任:Yongli Li, PhD、Henan Provincial People's Hospital
- 研究主任:Zhengqian Li, PhD、Peking University Third Hospital
- 首席研究员:Haoxiang Xu, Currently pursuing a master's、Henan Provincial People's Hospital
出版物和有用的链接
一般刊物
- Andreux PA, Blanco-Bose W, Ryu D, Burdet F, Ibberson M, Aebischer P, Auwerx J, Singh A, Rinsch C. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nat Metab. 2019 Jun;1(6):595-603. doi: 10.1038/s42255-019-0073-4. Epub 2019 Jun 14.
- Ganesan S, Magee M, Stone JE, Mulhall MD, Collins A, Howard ME, Lockley SW, Rajaratnam SMW, Sletten TL. The Impact of Shift Work on Sleep, Alertness and Performance in Healthcare Workers. Sci Rep. 2019 Mar 15;9(1):4635. doi: 10.1038/s41598-019-40914-x.
- Sen A, Tai XY. Sleep Duration and Executive Function in Adults. Curr Neurol Neurosci Rep. 2023 Nov;23(11):801-813. doi: 10.1007/s11910-023-01309-8. Epub 2023 Nov 14.
- Xu N, Du C, Yu Y, Li Y, Gao S, Yu S, Sun B, Lou H. Urolithin A improves Parkinson's disease-associated cognitive impairment through modulation of neuroinflammation and neuroplasticity. Exp Neurol. 2025 Nov;393:115395. doi: 10.1016/j.expneurol.2025.115395. Epub 2025 Jul 24.
- Hou Y, Chu X, Park JH, Zhu Q, Hussain M, Li Z, Madsen HB, Yang B, Wei Y, Wang Y, Fang EF, Croteau DL, Bohr VA. Urolithin A improves Alzheimer's disease cognition and restores mitophagy and lysosomal functions. Alzheimers Dement. 2024 Jun;20(6):4212-4233. doi: 10.1002/alz.13847. Epub 2024 May 16.
- Xiang J, Xu J, Zhang Y, Liu X. Urolithin A: Potential to enhance autophagic clearance and mitigate neuroinflammation in Alzheimer's disease. Ageing Res Rev. 2026 Jul;119:103157. doi: 10.1016/j.arr.2026.103157. Epub 2026 May 7.
- Song J, Feng P, Wu X, Li B, Su Y, Liu Y, Zheng Y. Individual Differences in the Neural Basis of Response Inhibition After Sleep Deprivation Are Mediated by Chronotype. Front Neurol. 2019 May 15;10:514. doi: 10.3389/fneur.2019.00514. eCollection 2019.
- Yang Z, Williams SD, Beldzik E, Anakwe S, Schimmelpfennig E, Lewis LD. Attentional failures after sleep deprivation are locked to joint neurovascular, pupil and cerebrospinal fluid flow dynamics. Nat Neurosci. 2025 Dec;28(12):2526-2536. doi: 10.1038/s41593-025-02098-8. Epub 2025 Oct 29.
- Bani Issa W, Abdul Rahman H, Albluwi N, Samsudin ABR, Abraham S, Saqan R, Naing L. Morning and evening salivary melatonin, sleepiness and chronotype: A comparative study of nurses on fixed day and rotating night shifts. J Adv Nurs. 2020 Dec;76(12):3372-3384. doi: 10.1111/jan.14530. Epub 2020 Sep 23.
- Choshen-Hillel S, Ishqer A, Mahameed F, Reiter J, Gozal D, Gileles-Hillel A, Berger I. Acute and chronic sleep deprivation in residents: Cognition and stress biomarkers. Med Educ. 2021 Feb;55(2):174-184. doi: 10.1111/medu.14296. Epub 2020 Aug 28.
- Phillips AJK, St Hilaire MA, Barger LK, O'Brien CS, Rahman SA, Landrigan CP, Lockley SW, Czeisler CA, Klerman EB. Predicting neurobehavioral performance of resident physicians in a Randomized Order Safety Trial Evaluating Resident-Physician Schedules (ROSTERS). Sleep Health. 2024 Feb;10(1S):S25-S33. doi: 10.1016/j.sleh.2023.10.018. Epub 2023 Nov 25.
- Williams GW, Shankar B, Klier EM, Chuang AZ, El Marjiya-Villarreal S, Nwokolo OO, Sharma A, Sereno AB. Sensorimotor and executive function slowing in anesthesiology residents after overnight shifts. J Clin Anesth. 2017 Aug;40:110-116. doi: 10.1016/j.jclinane.2017.04.002.
- Basner M, Dinges DF, Shea JA, Small DS, Zhu J, Norton L, Ecker AJ, Novak C, Bellini LM, Volpp KG. Sleep and Alertness in Medical Interns and Residents: An Observational Study on the Role of Extended Shifts. Sleep. 2017 Apr 1;40(4):zsx027. doi: 10.1093/sleep/zsx027.
- Rahman SA, Sullivan JP, Barger LK, St Hilaire MA, O'Brien CS, Stone KL, Phillips AJK, Klerman EB, Qadri S, Wright KP Jr, Halbower AC, Segar JL, McGuire JK, Vitiello MV, de la Iglesia HO, Poynter SE, Yu PL, Sanderson AL, Zee PC, Landrigan CP, Czeisler CA, Lockley SW; ROSTERS STUDY GROUP. Extended Work Shifts and Neurobehavioral Performance in Resident-Physicians. Pediatrics. 2021 Mar;147(3):e2020009936. doi: 10.1542/peds.2020-009936. Epub 2021 Feb 22.
- Mao T, Fang Z, Chai Y, Deng Y, Rao J, Quan P, Goel N, Basner M, Guo B, Dinges DF, Liu J, Detre JA, Rao H. Sleep deprivation attenuates neural responses to outcomes from risky decision-making. Psychophysiology. 2024 Apr;61(4):e14465. doi: 10.1111/psyp.14465. Epub 2023 Oct 31.
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- 2026-150
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
The scope, timing, and access procedures for sharing individual participant data are under consideration. Any future sharing would be limited to de-identified data made available to qualified researchers or research institutions for scientific purposes, subject to ethics committee requirements and applicable regulations.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.